Recombinant interleukin-6

{
  "id": "MLC-T-ONC-016441",
  "term": "Recombinant interleukin-6",
  "field": "Oncology and biomedicine",
  "definition": "A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine interleukin-6 (IL-6) with antiapoptotic, proinflammatory, antiinflammatory, proproliferative and proangiogenic activities. IL-6 binds to its receptor (IL-6R), activating a receptor-CD130 receptor complex; the CD130 portion of the complex is a signal transduction protein that activates JAK kinases and ras-mediated signaling pathways, which in turn activate downstream signaling pathways, resulting in the activation of various transcription factors (STAT, ELK-1, NF-IL-6, etc.) and gene transcription. The physiological effects of IL-6 are complex and varied and include hematopoietic, pyrogenic and thermogenic, proinflammatory, antiinflammatory, proproliferative (anti-apoptotic), and angiogenic effects.",
  "abbreviation": "HPGF",
  "synonyms": [
    "B-cell differentiation factor-2",
    "B-cell stimulatory factor-2",
    "hepatocyte-stimulating factor",
    "hybridoma growth factor",
    "IFN beta 2",
    "interleukin-6",
    "myeloid differentiation inducing protein",
    "plasmacytoma growth factor"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/recombinant-interleukin-6/"
}